SGLT2 inhibitors and their possible use in prevention and treatment of neurological diseases
DOI:
https://doi.org/10.56782/pps.176Keywords:
SGLT2 inhibitors, Alzheimer disease, Ischemic Stroke, Type 2 Diabetes, Autism spectrum disordersAbstract
Neurological diseases, neurological complications of diabetes and cardiovascular disease complications affecting the central nervous system (CNS) are one of the greatest challenges of modern medicine. Many of these diseases require the introduction of new therapies to improve the prognosis and quality of life of patients. Drugs with the increasing use in recent years are the SGLT2 inhibitors (SGLT2i): canagliflozin, dapagliflozin, empagliflozin. They demonstrate multiple pleiotropic actions with potential applications in CNS diseases. In addition to renal tubules, SGLT receptors are also found within the central nervous system. In numerous studies in animal models, SGLT2i have had promising results in the treatment of neurological conditions such as Alzheimer's disease, autism spectrum disorders, lesions caused by vascular diseases or complications of ischaemic stroke. SGLT2 inhibitors reduce oxidative stress and activation of inflammatory processes within the CNS, which may in the future be used to treat neurological diseases. So far, published studies on the effects of SGLT2 inhibitors on the nervous system are promising, but extensive, multicentre randomised trials on large groups of patients are needed to understand the exact mechanisms of action, therapeutic effects and potential side effects of SGLT2i.
Downloads
References
Ong, K.L.; Stafford, L.K.; McLaughlin, S.A.; Boyko, E.J.; Vollset, S.E.; Smith, A.E.; Dalton, B.E.; Duprey, J.; Cruz, J.A.; Hagins, H.; i in. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2023, 402, 203-234, DOI:10.1016/S0140-6736(23)01301-6. DOI: https://doi.org/10.1016/S0140-6736(23)01301-6
Kanaley, J.A.; Colberg, S.R.; Corcoran, M.H.; Malin, S.K.; Rodriguez, N.R.; Crespo, C.J.; Kirwan, J.P.; Zierath, J.R. Exercise/Physical Activity in Individuals with Type 2 Diabetes: A Consensus Statement from the American College of Sports Medicine. Med. Sci. Sports. Exerc. 2022, 54, 353-368. DOI:10.1249/MSS.0000000000002800. DOI: https://doi.org/10.1249/MSS.0000000000002800
Bertoluci, M.C.; Rocha, V.Z. Cardiovascular risk assessment in patients with diabetes. Diabetol. Metab. Syndr. 2017, 9, Art. No: 25. DOI:10.1186/S13098-017-0225-1. DOI: https://doi.org/10.1186/s13098-017-0225-1
Pawlos, A.; Broncel, M.; Woźniak, E.; Gorzelak-Pabiś, P. Neuroprotective Effect of SGLT2 Inhibitors. Molecules 2021, 26, Art. No: 7213. DOI:10.3390/MOLECULES26237213. DOI: https://doi.org/10.3390/molecules26237213
Nguyen, T.T.; Ta, Q.T.H.; Nguyen, T.K.O.; Nguyen, T.T.D.; Giau, V. Van Type 3 Diabetes and Its Role Implications in Alzheimer’s Disease. Int. J. Mol. Sci. 2020, 21, Art. No: 3165. DOI:10.3390/IJMS21093165. DOI: https://doi.org/10.3390/ijms21093165
Yu, J.; Lee, S.H.; Kim, M.K. Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus. Endocrinol. Metab. 2022, 37, 26-37. DOI:10.3803/ENM.2022.105. DOI: https://doi.org/10.3803/EnM.2022.105
Cowie, M.R.; Fisher, M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nature reviews. Cardiology 2020, 17, 761–772. DOI:10.1038/S41569-020-0406-8. DOI: https://doi.org/10.1038/s41569-020-0406-8
Herrera-González, A.; Núñez-López, G.; Núñez-Dallos, N.; Amaya-Delgado, L.; Sandoval, G.; Remaud-Simeon, M.; Morel, S.; Arrizon, J.; Hernández, L. Enzymatic synthesis of phlorizin fructosides. Enzyme Microb. Technol. 2021, 147, Art. No: 109783. DOI:10.1016/J.ENZMICTEC.2021.109783. DOI: https://doi.org/10.1016/j.enzmictec.2021.109783
Shubrook, J.H.; Bokaie, B.B.; Adkins, S.E. Empagliflozin in the treatment of type 2 diabetes: Evidence to date. Drug Des. Devel. Ther. 2015, 9, 5793–5803. DOI:10.2147/DDDT.S69926. DOI: https://doi.org/10.2147/DDDT.S69926
Chawla, G.; Chaudhary, K.K. A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Diabetes Metab. Syndr. 2019, 13, 2001–2008. DOI:10.1016/J.DSX.2019.04.035. DOI: https://doi.org/10.1016/j.dsx.2019.04.035
Packer, M. Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine? Nat. Cardiovasc. Res. 2, 2023, 705–707. DOI: 10.1038/s44161-023-00306-x DOI: https://doi.org/10.1038/s44161-023-00306-x
Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchet, D.; Bluhmki, E.; Hantel, S.; Matheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; i in. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Eng. J. Med 2015, 373, 17–18. DOI:10.1056/NEJMOA1504720. DOI: https://doi.org/10.1056/NEJMoa1504720
Muskiet, M.H.A.; van Raalte, D.H.; van Bommel, E.; Smits, M.M.; Tonneijck, L. Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol. 2015, 3, 928–929. DOI:10.1016/S2213-8587(15)00424-6. DOI: https://doi.org/10.1016/S2213-8587(15)00424-6
Vallon, V.; Platt, K.A.; Cunard, R.; Schroth, J.; Whaley, J.; Thomson, S.C.; Koepsell, H.; Rieg, T. SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule. J. Am. Soc. Nephrol. 2011, 22, 104-112. DOI:10.1681/ASN.2010030246. DOI: https://doi.org/10.1681/ASN.2010030246
Vallon, V.; Verma, S. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. Annu. Rev. Physiol. 2021, 83, 503–528. DOI:10.1146/annurev-physiol-031620-095920. DOI: https://doi.org/10.1146/annurev-physiol-031620-095920
Chao, E.C.; Henry, R.R. SGLT2 inhibition — a novel strategy for diabetes treatment. Nat. Rev. Drug Discov. 2010, 9, 551–559. DOI:10.1038/nrd3180. DOI: https://doi.org/10.1038/nrd3180
Qiu, M.; Ding, L.L.; Zhang, M.; Zhou, H.R. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. Diab. Vasc. Dis. Res. 2021, 18. DOI:10.1177/14791641211011016. DOI: https://doi.org/10.1177/14791641211011016
Ujjawal, A.; Schreiber, B.; Verma, A. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidneytransplant recipients: what is the evidence? Ther. Adv. Endocrinol. Metab. 2022, 13. DOI:10.1177/20420188221090001. DOI: https://doi.org/10.1177/20420188221090001
Yu, A.S.; Hirayama, B.A.; Timbol, G.; Liu, J.; Diez-Sampedro, A.; Kepe, V.; Satyamurthy, N.; Huang, S.C.; Wright, E.M.; Barrio, J.R. Regional distribution of SGLT activity in rat brain in vivo. Am. J. Physiol 2013, 304. DOI:10.1152/AJPCELL.00317.2012. DOI: https://doi.org/10.1152/ajpcell.00317.2012
Shah, K.; DeSilva, S.; Abbruscato, T. The Role of Glucose Transporters in Brain Disease: Diabetes and Alzheimer’s Disease. Int. J. Mol. Sci. 2012, 13, Art. No: 12629. DOI:10.3390/IJMS131012629. DOI: https://doi.org/10.3390/ijms131012629
Wright, E.M.; Loo, D.D.; Hirayama, B.A. Biology of human sodium glucose transporters. Physiol. Rev. 2011, 91, 733–794. DOI:10.1152/PHYSREV.00055.2009. DOI: https://doi.org/10.1152/physrev.00055.2009
Nguyen, T.; Wen, S.; Gong, M.; Yuan, X.; Xu, D.; Wang, C.; Jin, J.; Zhou, L. Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice. Diabet. Met. Synd. Ob. 2020, 13, 2781–2799. DOI:10.2147/DMSO.S258593. DOI: https://doi.org/10.2147/DMSO.S258593
Enerson, B.E.; Drewes, L.R. The rat blood-brain barrier transcriptome. J. Cereb. Blood Flow Meta. 2006, 26, 959–973. DOI:10.1038/SJ.JCBFM.9600249. DOI: https://doi.org/10.1038/sj.jcbfm.9600249
Koepsell, H. Glucose transporters in brain in health and disease. Pflug. Arch. 2020, 472, 1299–1343. DOI:10.1007/S00424-020-02441-X. DOI: https://doi.org/10.1007/s00424-020-02441-x
Oerter, S.; Förster, C.; Bohnert, M. Validation of sodium/glucose cotransporter proteins in human brain as a potential marker for temporal narrowing of the trauma formation. Int. J. Legal Med. 2019, 133, 1107–1114. DOI:10.1007/S00414-018-1893-6. DOI: https://doi.org/10.1007/s00414-018-1893-6
Tahara, A.; Takasu, T.; Yokono, M.; Imamura, M.; Kurosaki, E. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J. Pharmacol. Sci. 2016, 130, 159–169. DOI:10.1016/J.JPHS.2016.02.003. DOI: https://doi.org/10.1016/j.jphs.2016.02.003
Cinti, F.; Moffa, S.; Impronta, F.; Cefalo, C.M.A.; Sun, V.A.; Sorice, G.; Mezza, T.; Giaccari, A. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Des. Devel. Ther. 2017, 11, 2905. DOI:10.2147/DDDT.S114932. DOI: https://doi.org/10.2147/DDDT.S114932
Malhotra, A.; Kudyar, S.; Gupta, A.K.; Kudyar, R.P.; Malhotra, P. Sodium glucose co-transporter inhibitors – A new class of old drugs. Int. J. Appl. Basic Med. Res. 2015, 5, 161. DOI:10.4103/2229-516X.165363. DOI: https://doi.org/10.4103/2229-516X.165363
Zhang, J.; Chen, C.; Hua, S.; Liao, H.; Wang, M.; Xiong, Y.; Cao, F. An updated meta-analysis of cohort studies: Diabetes and risk of Alzheimer’s disease. Diabetes Res. Clin. Pract. 2017, 124, 41–47. DOI:10.1016/J.DIABRES.2016.10.024. DOI: https://doi.org/10.1016/j.diabres.2016.10.024
Khan, S.; Barve, K.H.; Kumar, M.S. Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease. Curr. Neuropharmacol. 2020, 18, 1106. DOI:10.2174/1570159X18666200528142429. DOI: https://doi.org/10.2174/1570159X18666200528142429
Scheltens, P.; De Strooper, B.; Kivipelto, M.; Holstege, H.; Chételat, G.; Teunissen, C.E.; Cummings, J.; van der Flier, W.M. Alzheimer’s disease. Lancet 2021, 397, 1577-1590. DOI:10.1016/S0140-6736(20)32205-4. DOI: https://doi.org/10.1016/S0140-6736(20)32205-4
Jasleen, B.; Vishal, G.K.; Sameera, M.; Fahad, M.; Brendan, O.; Deion, S.; Pemminati, S. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk. Cureus 2023, 15, Art. No: e33939. DOI:10.7759/CUREUS.33939. DOI: https://doi.org/10.7759/cureus.33939
Lin, B.; Koibuchi, N.; Hasegawa, Y.; Sueta, D.; Toyama, K.; Uekawa, K.; Ma, M.J.; Nakagawa, T.; Kusaka, H.; Kim-Mitsuyama, S. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc. Diabetol. 2014, 13, 148. DOI:10.1186/S12933-014-0148-1. DOI: https://doi.org/10.1186/s12933-014-0148-1
Gao, L.; Zhang, Y.; Sterling, K.; Song, W. Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential. Transl. Neurodegener. 2022, 11, Art. No: 4. DOI:10.1186/S40035-022-00279-0. DOI: https://doi.org/10.1186/s40035-022-00279-0
Jha, D.; Bakker, E.N.T.P.; Kumar, R. Mechanistic and therapeutic role of NLRP3 inflammasome in the pathogenesis of Alzheimer’s disease. J. Neurochem. 2023, 00, 1–25. DOI:10.1111/JNC.15788. DOI: https://doi.org/10.1111/jnc.15788
Kim, S.R.; Lee, S.G.; Kim, S.H.; Kim, J.H.; Choi, E.; Cho, W.; Rim, J.H.; Hwang, I.; Lee, C.J.; Lee, M.; i in. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat. Commun. 2020, 11, Art. No: 2127. DOI:10.1038/S41467-020-15983-6. DOI: https://doi.org/10.1038/s41467-020-15983-6
Barrett, T.J. Macrophages in Atherosclerosis Regression. Arterioscler. Thromb. Vasc. Biol. 2020, 40, 20–33. DOI:10.1161/ATVBAHA.119.312802. DOI: https://doi.org/10.1161/ATVBAHA.119.312802
Xu, L.; Nagata, N.; Nagashimada, M.; Zhuge, F.; Ni, Y.; Chen, G.; Mayoux, E.; Kaneko, S.; Ota, T. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice. EBioMedicine 2017, 20, 137–149. DOI:10.1016/j.ebiom.2017.05.028. DOI: https://doi.org/10.1016/j.ebiom.2017.05.028
Miyachi, Y.; Tsuchiya, K.; Shiba, K.; Mori, K.; Komiya, C.; Ogasawara, N.; Ogawa, Y. A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition. Sci. Rep. 2018, 8, 1–13. DOI:10.1038/s41598-018-34305-x. DOI: https://doi.org/10.1038/s41598-018-34305-x
Erichsen, J.; Craft, S. Targeting immunometabolic pathways for combination therapy in Alzheimer’s disease. Alzheimers Dement. (N Y), 2023, 9, Art. No: e12423. DOI: 10.1002/TRC2.12423 DOI: https://doi.org/10.1002/trc2.12423
Wium-Andersen, I.K.; Osler, M.; Jørgensen, M.B.; Rungby, J.; Wium-Andersen, M.K. Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study. Eur. J. Endocrinol. 2019, 181, 499–507. DOI:10.1530/EJE-19-0259. DOI: https://doi.org/10.1530/EJE-19-0259
Avgerinos, K.I.; Mullins, R.J.; Vreones, M.; Mustapic, M.; Chen, Q.; Melvin, D.; Kapogiannis, D.; Egan, J.M. Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics. Cells 2022, 11, Art. No: 3372 DOI:10.3390/CELLS11213372. DOI: https://doi.org/10.3390/cells11213372
Sȩdzikowska, A.; Szablewski, L. Insulin and Insulin Resistance in Alzheimer’s Disease. Int. J. Mol. Sci. 2021, 22, Art. No: 9987. DOI:10.3390/IJMS22189987. DOI: https://doi.org/10.3390/ijms22189987
Kullmann, S.; Hummel, J.; Wagner, R.; Dannecker, C.; Vosseler, A.; Fritsche, L.; Veit, R.; Kantartzis, K.; Machann, J.; Birkenfeld, A.L.; i in. Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial. Diabetes Care 2022, 45, 398–406. DOI:10.2337/DC21-1136. DOI: https://doi.org/10.2337/dc21-1136
Zhao, Y.; Zhang, X.; Chen, X.; Wei, Y. Neuronal injuries in cerebral infarction and ischemic stroke: From mechanisms to treatment (Review). Int. J. Mol. Med. 2022, 49, 15. DOI:10.3892/IJMM.2021.5070. DOI: https://doi.org/10.3892/ijmm.2021.5070
Orellana-Urzúa, S.; Rojas, I.; Líbano, L.; Rodrigo, R. Pathophysiology of Ischemic Stroke: Role of Oxidative Stress. Curr. Pharm. Des. 2020, 26, 4246–4260. DOI:10.2174/1381612826666200708133912. DOI: https://doi.org/10.2174/1381612826666200708133912
Abdel-latif, R.G.; Rifaai, R.A.; Amin, E.F. Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia/reperfusion injury through HIF-1α/VEGF signaling pathway. Arch. Pharm. Res. 2020, 43, 514–525. DOI:10.1007/S12272-020-01237-Y. DOI: https://doi.org/10.1007/s12272-020-01237-y
Zheng, J.; Chen, P.; Zhong, J.; Cheng, Y.; Chen, H.; He, Y.; Chen, C. HIF-1α in myocardial ischemia-reperfusion injury. Mol. Med. Rep. 2021, 23, DOI:10.3892/MMR.2021.11991. DOI: https://doi.org/10.3892/mmr.2021.11991
Xing, J.; Lu, J. HIF-1α Activation Attenuates IL-6 and TNF-α Pathways in Hippocampus of Rats Following Transient Global Ischemia. Cell. Pchysiol. Biochem. 2016, 39, 511–520. DOI:10.1159/000445643. DOI: https://doi.org/10.1159/000445643
Al Hamed, F.A.; Elewa, H. Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke. Clin. Ther. 2020, 42, e242–e249. DOI:10.1016/j.clinthera.2020.09.008. DOI: https://doi.org/10.1016/j.clinthera.2020.09.008
Moon, S.; Chang, M.S.; Koh, S.H.; Choi, Y.K. Repair Mechanisms of the Neurovascular Unit after Ischemic Stroke with a Focus on VEGF. Int. J. Mol. Sci. 2021, 22, Art. No: 8543. DOI:10.3390/IJMS22168543. DOI: https://doi.org/10.3390/ijms22168543
Wiciński, M.; Wódkiewicz, E.; Górski, K.; Walczak, M.; Malinowski, B. Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury. Pharmaceuticals 2020, 13 (11), Art. No: 379. DOI:10.3390/PH13110379. DOI: https://doi.org/10.3390/ph13110379
Geiseler, S.J.; Morland, C. The Janus Face of VEGF in Stroke. Int. J. Mol. Sci. 2018, 19, Art. No: 1362. DOI:10.3390/IJMS19051362. DOI: https://doi.org/10.3390/ijms19051362
Chiarotti, F.; Venerosi, A. Epidemiology of Autism Spectrum Disorders: A Review of Worldwide Prevalence Estimates Since 2014. Brain Sci. 2020, 10, 274, DOI:10.3390/BRAINSCI10050274. DOI: https://doi.org/10.3390/brainsci10050274
Wang, L.; Wang, B.; Wu, C.; Wang, J.; Sun, M. Autism Spectrum Disorder: Neurodevelopmental Risk Factors, Biological Mechanism, and Precision Therapy. Int. J. Mol. Sci. 2023, 24, DOI:10.3390/IJMS24031819. DOI: https://doi.org/10.3390/ijms24031819
Elsabbagh, M.; Divan, G.; Koh, Y.J.; Kim, Y.S.; Kauchali, S.; Marcín, C.; Montiel-Nava, C.; Patel, V.; Paula, C.S.; Wang, C.; i in. Global prevalence of autism and other pervasive developmental disorders. Autism Res. 2012, 5, 160–179. DOI:10.1002/AUR.239. DOI: https://doi.org/10.1002/aur.239
Jayaprakash, P.; Isaev, D.; Shabbir, W.; Lorke, D.E.; Sadek, B.; Oz, M. Curcumin Potentiates α7 Nicotinic Acetylcholine Receptors and Alleviates Autistic-Like Social Deficits and Brain Oxidative Stress Status in Mice. Int. J. Mol. Sci. 2021, 22, Art. No: 7251. DOI:10.3390/IJMS22147251. DOI: https://doi.org/10.3390/ijms22147251
Bjørklund, G.; Meguid, N.A.; El-Bana, M.A.; Tinkov, A.A.; Saad, K.; Dadar, M.; Hemimi, M.; Skalny, A. V.; Hosnedlová, B.; Kizek, R.; i in. Oxidative Stress in Autism Spectrum Disorder. Mol. Neurobiol. 2020, 57, 2314–2332. DOI:10.1007/S12035-019-01742-2. DOI: https://doi.org/10.1007/s12035-019-01742-2
Nakhal, M.M.; Aburuz, S.; Sadek, B.; Akour, A. Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder. Molecules 2022, 27, Art. No: 7174. DOI:10.3390/MOLECULES27217174. DOI: https://doi.org/10.3390/molecules27217174
Nakhal, M.M.; Jayaprakash, P.; Aburuz, S.; Sadek, B.; Akour, A. Canagliflozin Ameliorates Oxidative Stress and Autistic-like Features in Valproic-Acid-Induced Autism in Rats: Comparison with Aripiprazole Action. Pharmaceuticals 2023, 16, 769, DOI:10.3390/PH16050769. DOI: https://doi.org/10.3390/ph16050769
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Mateusz Sobczyk, Daria Żuraw, Paulina Oleksa, Kacper Jasiński, Mikołaj Porzak, Michał Dacka
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
